1. Application of a sensitive and accurate LC-MS/MS method for determination of dryocrassin ABBA in rat plasma for a bioavailability study
- Author
-
Fu-Qiang Li, Zhuo Liu, and Ya-Ming Ding
- Subjects
Pharmacology ,Analyte ,Chromatography ,Chemistry ,Formic acid ,Elution ,Clinical Biochemistry ,Selected reaction monitoring ,General Medicine ,Mass spectrometry ,Biochemistry ,Analytical Chemistry ,Bioavailability ,chemistry.chemical_compound ,Column chromatography ,Drug Discovery ,Molecular Biology ,Ammonium acetate - Abstract
A sensitive and accurate liquid chromatography–tandem mass spectrometry method was developed and validated for the determination of dryocrassin ABBA, a potential active component isolated from Dryopteris crassirhizoma, in rat plasma. Chromatographic separation was achieved on a Zorbax SB-C18 column (50 × 2.1 mm, 1.8 µm), with elution consisting of eluent (A) 10 mm ammonium acetate in methanol containing 0.1% formic acid and (B) 10 mm ammonium acetate in water containing 0.1% formic acid (A:B = 99:1, v/v) at a flow rate of 0.3 mL/min. Multiple reaction monitoring mode was used to monitor the precursor–product ion transitions of m/z 819.3 403.4 for dryocrassin ABBA and m/z 426.2 409.2 for internal standard. This assay exhibited a good linearity with a correlation coefficient >0.99 and showed no endogenous interference with the analyte and internal standard. The lower limit of quantification of dryocrassin ABBA was 4 ng/mL in 50 μL of rat plasma. The method was successfully applied in the pharmacokinetic study of dryocrassin ABBA in rats after intravenous (2.35 mg/kg) and oral (23.5 mg/kg) doses of dryocrassin ABBA. The oral bioavailability (F) of dryocrassin ABBA was estimated to be 50.1%. Our study is the first to clarify the pharmacokinetic behaviors of dryocrassin ABBA in animals. Copyright © 2014 John Wiley & Sons, Ltd.
- Published
- 2014
- Full Text
- View/download PDF